Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

Xing Guo Wang; Thomas Jandl; Ekaterina Dadachova; Ekaterina Revskaya

doi:10.4155/tde.13.137

Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

Xing Guo Wang
, Thomas Jandl
, Ekaterina Dadachova
, Ekaterina Revskaya

Medical Oncology

Hubei University
Albert Einstein College of Medicine

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC ₅₀ of 120 ng/ml. ¹²⁵I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi ¹⁸⁸Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

Original language	English
Pages (from-to)	139-147
Number of pages	9
Journal	Therapeutic Delivery
Volume	5
Issue number	2
DOIs	https://doi.org/10.4155/tde.13.137
State	Published - Feb 2014

Access to Document

10.4155/tde.13.137

Cite this

@article{1392c8f1831a40898e5260759cade410,

title = "Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice",

abstract = "Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4\% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.",

author = "Wang, \{Xing Guo\} and Thomas Jandl and Ekaterina Dadachova and Ekaterina Revskaya",

year = "2014",

month = feb,

doi = "10.4155/tde.13.137",

language = "English",

volume = "5",

pages = "139--147",

journal = "Therapeutic Delivery",

issn = "2041-5990",

number = "2",

}

TY - JOUR

T1 - Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

AU - Wang, Xing Guo

AU - Jandl, Thomas

AU - Dadachova, Ekaterina

AU - Revskaya, Ekaterina

PY - 2014/2

Y1 - 2014/2

N2 - Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

AB - Background: There is a need for novel treatments of advanced cervical cancer. We investigated the utility of recombinant human TNF-related apoptosis-inducing ligand (rhTRAIL), a molecule capable of inducing apoptosis in cancer cells, for the therapy of CasKi cervical cancer xenografts in nude mice. Results: CasKi cells proved to be sensitive in vitro to rhTRAIL with an IC 50 of 120 ng/ml. 125I-tagged rhTRAIL specifically accumulated in CasKi tumors in mice with the highest uptake of 9.4% ID/g at 2 h post-injection. Both naive and 200 μCi 188Re-tagged rhTRAIL administered in the amount of 0.35 mg/kg body weight significantly retarded CasKi tumor growth to the same extent in mice without the side effects of cisplatin chemotherapeutic control. Conclusion: rhTRAIL is a promising novel agent for treatment of advanced cervical cancer.

UR - https://www.scopus.com/pages/publications/84893241011

U2 - 10.4155/tde.13.137

DO - 10.4155/tde.13.137

M3 - Article

C2 - 24483193

AN - SCOPUS:84893241011

SN - 2041-5990

VL - 5

SP - 139

EP - 147

JO - Therapeutic Delivery

JF - Therapeutic Delivery

IS - 2

ER -

Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice

Abstract

Access to Document

Other files and links

Fingerprint

Cite this